Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NELARABINE vs AURLUMYN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nelarabine is a prodrug of ara-G, a deoxyguanosine analog. It is converted to ara-GTP, which accumulates in T-cells and inhibits DNA synthesis, leading to cell death.
Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.
T-cell acute lymphoblastic leukemia (T-ALL),T-cell lymphoblastic lymphoma (T-LBL),Relapsed or refractory T-ALL/T-LBL
Treatment of relapsed or refractory multiple myeloma,Treatment of relapsed or refractory mantle cell lymphoma
1500 mg/m2 intravenously over 2 hours on days 1, 3, and 5, repeated every 28 days.
Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.
Terminal t1/2: 30 hours (range 21-48 h) in adults; prolonged in renal impairment. Ara-G (active metabolite) t1/2: 3 hours.
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 30-40 hours in severe renal impairment (Cr Cl <30 m L/min).
Nelarabine is demethylated by adenosine deaminase (ADA) to ara-G, which is then phosphorylated to ara-GTP intracellularly. It is partially metabolized by aldehyde oxidase.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C8.
Renal: 50-60% as unchanged ara-G; fecal: <5% as metabolites; biliary: negligible.
Primarily renal excretion of unchanged drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
<25% bound to plasma proteins (albumin).
Approximately 85-90% bound to serum albumin.
Vd: 197 L/m² (approx 5.6 L/kg based on 1.73 m²/70 kg), indicating extensive tissue distribution.
0.5 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration.
IV only; oral bioavailability not established (<5% due to extensive first-pass metabolism).
Oral bioavailability is 50-60% due to first-pass metabolism and incomplete absorption.
Cr Cl 30-60 m L/min: reduce dose to 975 mg/m2. Cr Cl <30 m L/min: not recommended.
GFR ≥30 m L/min: no adjustment. GFR <30 m L/min: not recommended (no data).
Child-Pugh Class B or C: reduce dose to 975 mg/m2. No data for severe impairment.
Child-Pugh A: no adjustment. Child-Pugh B or C: not recommended (no data).
650 mg/m2 intravenously over 1 hour daily for 5 consecutive days, repeated every 21 days.
Not established; safety and efficacy not determined in pediatric patients.
No specific dose adjustment recommended; monitor renal function and hematologic toxicity closely.
No specific dose adjustment; monitor renal function and hematologic toxicity more frequently.
Severe neurotoxicity, including Guillain-Barré-like syndrome, peripheral neuropathy, and CNS demyelination. Avoid in patients with severe pre-existing neurological conditions.
None.
Monitor for neurological toxicity; may require discontinuation.,Hematologic toxicity: neutropenia, thrombocytopenia, anemia.,Increased risk of infection.,Tumor lysis syndrome prophylaxis required.,Hepatotoxicity and renal toxicity.
Hematologic toxicity (neutropenia, thrombocytopenia, anemia), infection risk, peripheral neuropathy, cardiotoxicity (heart failure), embryo-fetal toxicity.
Hypersensitivity to nelarabine or its components.,Severe pre-existing neurological disorders (e.g., Guillain-Barré syndrome, peripheral neuropathy).,Pregnancy (may cause fetal harm).
Hypersensitivity to AURLUMYN or any of its components.
No known food interactions. Maintain adequate hydration to prevent tumor lysis syndrome. Avoid grapefruit juice? No evidence for interaction.
Avoid alcohol. No specific food interactions, but maintain a balanced diet. Take with food or milk if gastrointestinal upset occurs.
Nelarabine is embryotoxic and fetotoxic in animal studies. It is classified as FDA Pregnancy Category D. There is evidence of fetal harm in pregnant women, including increased risk of congenital malformations, intrauterine growth restriction, and fetal death. Use during the first trimester carries highest risk of major malformations; second and third trimester exposure may cause myelosuppression and low birth weight. Avoid in pregnancy unless benefit outweighs risk.
First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid in pregnancy unless benefit outweighs risk.
No human data on nelarabine excretion in breast milk. Due to its mechanism of action (DNA synthesis inhibition) and potential for serious adverse effects in the nursing infant, breastfeeding is contraindicated during therapy and for at least 3 months after the last dose.
No data on excretion in human milk; M/P ratio unknown. Due to potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose.
No established dose adjustments in pregnancy. Physiological changes in pregnancy (increased plasma volume, renal clearance, hepatic metabolism) may alter nelarabine pharmacokinetics, but no specific studies exist. Use standard weight-based dosing with careful monitoring for toxicity. Consider reducing dose if severe myelosuppression or neurotoxicity occurs.
No specific dosing adjustments established for pregnancy. Pregnancy-induced pharmacokinetic changes (increased volume of distribution, enhanced renal clearance) may reduce drug exposure; consider therapeutic drug monitoring if available.
Administer intravenously over 2 hours. Monitor for neurological toxicity including somnolence, ataxia, and seizures. Premedicate with antiemetics. Use in T-cell acute lymphoblastic leukemia/lymphoma after failure of two prior regimens. Contraindicated in severe renal impairment (Cr Cl <30 m L/min).
AURLUMYN is a proprietary name for auranofin, an oral gold compound used for rheumatoid arthritis. Monitor for oral ulcerations, dermatitis, and proteinuria. Renal function and CBC should be checked monthly. Avoid concurrent use with penicillamine, antimalarials, immunosuppressants, or cytotoxic drugs. Onset of action may be delayed 3-6 months.
This drug can cause severe drowsiness and coordination problems; do not drive or operate machinery until you know how it affects you.,Report any unusual tiredness, muscle weakness, or tingling in hands/feet to your doctor immediately.,If you experience seizures, loss of consciousness, or confusion, seek emergency medical attention.,You will have regular blood tests to monitor your blood cell counts and kidney function.,This drug can cause serious infections; wash hands frequently and avoid crowds.,Use effective contraception during treatment and for at least 3 months after stopping.,Do not receive live vaccines during therapy without consulting your doctor.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,Report any mouth sores, skin rash, unexplained bruising, or change in urine color immediately.,Regular blood and urine tests are required to monitor for side effects.,May take 3-6 months to feel full benefit; do not stop suddenly.,Avoid alcohol as it may increase risk of liver toxicity.,Use effective contraception during treatment and for 6 months after stopping.,Do not take any other medications (including OTC) without approval from your doctor.
"Roflumilast may increase the immunosuppressive activities of Nelarabine."
"The risk or severity of adverse effects can be increased when Docetaxel is combined with Nelarabine."
"Nelarabine may decrease the cardiotoxic activities of Acetyldigitoxin."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NELARABINE vs AURLUMYN, answered by our medical review team.
NELARABINE is a Antineoplastic Agent that works by Nelarabine is a prodrug of ara-G, a deoxyguanosine analog. It is converted to ara-GTP, which accumulates in T-cells and inhibits DNA synthesis, leading to cell death.. AURLUMYN is a Antineoplastic Agent that works by Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NELARABINE and AURLUMYN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NELARABINE is: 1500 mg/m2 intravenously over 2 hours on days 1, 3, and 5, repeated every 28 days.. The standard adult dose of AURLUMYN is: Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NELARABINE and AURLUMYN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NELARABINE is classified as Category C. Nelarabine is embryotoxic and fetotoxic in animal studies. It is classified as FDA Pregnancy Category D. There is evidence of fetal harm in pregnant women, including increased risk. AURLUMYN is classified as Category C. First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.